{
    "id": "correct_subsidiary_00058_0",
    "rank": 28,
    "data": {
        "url": "https://pink.citeline.com/PS029572/In-Brief-Elan-selegilene",
        "read_more_link": "",
        "language": "en",
        "title": "In Brief: Elan selegilene",
        "top_image": "http://pink.citeline.com/-/media/icons/2023/pink_citeline_158.png?rev=cb261f74c0d2448085ca73945c77ccaf",
        "meta_img": "http://pink.citeline.com/-/media/icons/2023/pink_citeline_158.png?rev=cb261f74c0d2448085ca73945c77ccaf",
        "images": [
            "https://pink.citeline.com/-/media/icons/2023/pink-sheet_domain_pos_rgb.png?rev=1dd7601600144594a8ec74ff6df8b547",
            "https://pink.citeline.com/-/media/icons/2023/pink_citeline_greyscale.png?rev=6b1ffa05a8e647db9ad3e9ec68a82115",
            "https://pink.citeline.com/dist/img/arrow.png",
            "https://pink.citeline.com/-/media/icons/2023/citeline_logo_footer.png?rev=317781d93d4a4821951866c7e7ab631c"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "The Pink Sheet"
        ],
        "publish_date": "1997-01-20T10:00:00+00:00",
        "summary": "",
        "meta_description": "Elan selegilene: Company acquires rights to fast-dissolving selegilene formulation using R.P. Scherer's Zydis technology in North America, U.K. and Ireland. Selegilene Zydis will be marketed in the U.S. by Elan subsidiary Athena Neurosciences. The product is in Phase III in the U.S. for Parkinson's disease...",
        "meta_lang": "",
        "meta_favicon": "/-/media/icons/2023/favicon-regulatory.png?rev=786493faaab643039eba9fc8a0d3d3ea",
        "meta_site_name": "Pink Sheet",
        "canonical_link": "http://pink.citeline.com/PS029572/In-Brief-Elan-selegilene",
        "text": "Please make sure all fields are completed.\n\nPlease make sure you have filled out all fields\n\nPlease make sure you have filled out all fields\n\nPlease enter a valid e-mail address\n\nPlease enter a valid Phone Number\n\nAsk your question to our analysts\n\nCancel\n\nPlease make sure all fields are completed.\n\nPlease enter a valid e-mail address\n\nPlease make sure you have filled out all fields\n\nPlease make sure you have filled out all fields\n\nSubject: In Brief: Elan selegilene\n\nAdd a personalized message to your email\n\nCancel"
    }
}